BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
BetterLife's Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
Biotech psychedelics company BetterLife Pharma Inc. (OTCQB:BETRF) in collaboration with the Carleton University Dept. of Neuroscience has received funding from the Mitacs Accelerate Program for research into the antidepressant effects and action mechanism of BETR-001 in preclinical models of depression.
A Canadian non-profit organization, Mitacs is experienced in designing and delivering research and training programs. They network and partner with governments, the private sector, other non-profit organizations and universities toward innovation excellence.
The under-study drug, BETR-001, is a second-generation LSD derivative molecule that would mimic the therapeutic potential of LSD without causing psychedelic effects such as hallucinations. The compound is non-hallucinogenic as well as non-controlled, which makes self-administration plausible.
As part of the funded Mitacs Accelerate Program, Dr. Argel Aguilar-Valles (principal investigator) and Dr. Vern Lewis (postdoctoral fellow) will continue to work with the BetterLife team to assess the efficacy and action mechanism of BETR-001 in depression models established in their lab.
BetterLife's synthesis patent for BETR-001 therefore could help reduce the regulatory burden, and its pending patent for composition and method of use covers the treatment of depression, cluster headaches, and post-traumatic stress disorder, among neuro-psychiatric and neurological disorders.
The company's CEO, Dr. Ahmad Doroudian, stated that BetterLife's next goal is to bring the treatment to Investigational New Drug ("IND") application as soon as possible.
Biotech psychedelics company BetterLife Pharma Inc. (OTCQB:BETRF) in collaboration with the Carleton University Dept. of Neuroscience has received funding from the Mitacs Accelerate Program for research into the antidepressant effects and action mechanism of BETR-001 in preclinical models of depression.
生物技術迷幻藥公司BetterLife Pharma Inc.(場外交易代碼：BETRF)與卡爾頓大學系神經科學系已收到來自Mitacs加速計劃目的：研究BETR-001在抑鬱症臨牀前模型中的抗抑鬱作用及其作用機制。
A Canadian non-profit organization, Mitacs is experienced in designing and delivering research and training programs. They network and partner with governments, the private sector, other non-profit organizations and universities toward innovation excellence.
Mitacs是一家加拿大非營利性組織，在設計和提供研究和培訓計劃方面經驗豐富。他們與政府、私營部門、其他非營利組織和大學建立網絡並建立合作伙伴關係，以實現卓越的創新。
The under-study drug, BETR-001, is a second-generation LSD derivative molecule that would mimic the therapeutic potential of LSD without causing psychedelic effects such as hallucinations. The compound is non-hallucinogenic as well as non-controlled, which makes self-administration plausible.
正在研究中的藥物，BETR-001，是一種第二代LSD衍生物分子這將模仿LSD的治療潛力，而不會引起幻覺等迷幻效應。這種化合物既不致幻，也不受控制，這使得自治看似合理。
As part of the funded Mitacs Accelerate Program, Dr. Argel Aguilar-Valles (principal investigator) and Dr. Vern Lewis (postdoctoral fellow) will continue to work with the BetterLife team to assess the efficacy and action mechanism of BETR-001 in depression models established in their lab.
作為資助的Mitacs加速計劃的一部分，阿蓋爾·阿吉拉爾-瓦萊斯博士(首席研究員)和Vern Lewis博士(博士後研究員)將繼續與BetterLife團隊合作，在他們的實驗室建立的抑鬱症模型中評估BETR-001的療效和作用機制。
BetterLife's synthesis patent for BETR-001 therefore could help reduce the regulatory burden, and its pending patent for composition and method of use covers the treatment of depression, cluster headaches, and post-traumatic stress disorder, among neuro-psychiatric and neurological disorders.
因此，BetterLife的BETR-001合成專利可以幫助減輕監管負擔，其正在申請的組合物和使用方法專利涵蓋治療抑鬱症、叢集性頭痛和創傷後應激障礙，以及神經精神和神經障礙。
The company's CEO, Dr. Ahmad Doroudian, stated that BetterLife's next goal is to bring the treatment to Investigational New Drug ("IND") application as soon as possible.
這個公司首席執行官艾哈邁德·多魯迪安博士，表示BetterLife的下一個目標是儘快將這種治療方法應用於研究新藥(“IND”)。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧